1 – 7 of 7
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours
2024) In BJU International(
- Contribution to journal › Article
-
Mark
Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort : The Swedish Norwegian Testicular Cancer Group Experience
(
- Contribution to journal › Article
- 2023
-
Mark
Validation of a prediction model for post-chemotherapy fibrosis in nonseminoma patients
(
- Contribution to journal › Article
- 2022
-
Mark
Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group
(
- Contribution to journal › Article
- 2021
-
Mark
Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid : Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden
(
- Contribution to journal › Article
- 2020
-
Mark
Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour : A Population-based Study from the Swedish Norwegian Testicular Cancer Group
(
- Contribution to journal › Article
- 2015
-
Mark
Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols
(
- Contribution to journal › Article